Triplet therapy with BRAF inhibitor, anti-EGFR agent, and MEK inhibitor in V600E BRAF–mutant colorectal cancer: A meta-analysis.

Category Systematic review
ConferenceASCO ANNUAL MEETING
Year 2025
This article has no abstract
Epistemonikos ID: 327140578b524bb53e73584ec01559f4e68660ff
First added on: Mar 25, 2026